Alkem Laboratories Ltd
NSE:ALKEM
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4 554.2
6 366.25
|
| Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
3M Co
NYSE:MMM
|
US |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
This alert will be permanently deleted.
Alkem Laboratories Ltd
Alkem Laboratories Ltd
Total Receivables
Alkem Laboratories Ltd
Total Receivables Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Receivables | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Alkem Laboratories Ltd
NSE:ALKEM
|
Total Receivables
₹30.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
|
Total Receivables
₹80.3B
|
CAGR 3-Years
17%
|
CAGR 5-Years
14%
|
CAGR 10-Years
N/A
|
|
|
Cipla Ltd
NSE:CIPLA
|
Total Receivables
₹55.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
7%
|
CAGR 10-Years
9%
|
|
|
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
|
Total Receivables
₹129.9B
|
CAGR 3-Years
9%
|
CAGR 5-Years
9%
|
CAGR 10-Years
10%
|
|
|
T
|
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
|
Total Receivables
₹17.9B
|
CAGR 3-Years
5%
|
CAGR 5-Years
3%
|
CAGR 10-Years
3%
|
|
|
M
|
Mankind Pharma Ltd
NSE:MANKIND
|
Total Receivables
₹9.4B
|
CAGR 3-Years
18%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Alkem Laboratories Ltd
Glance View
Alkem Laboratories Ltd. is a prominent player in the pharmaceutical industry, rooted in its commitment to research, development, and manufacturing of high-quality generic medications. Founded in 1973 and headquartered in Mumbai, India, Alkem has successfully carved out a significant market share in both domestic and international markets. With a diverse product portfolio encompassing over 700 generics across various therapeutic categories, the company's innovative approach and stringent adherence to regulatory compliance have earned it a robust reputation. Alkem's strategic focus on expanding its presence in key global markets, particularly the United States, positions it well to capitalize on the growing demand for affordable healthcare solutions. As investors look for opportunities in the pharmaceutical sector, Alkem Laboratories stands out not just for its ambitious growth trajectory, but also for its proven track record of delivering consistent financial performance. The company's recent investments in state-of-the-art facilities and research initiatives underscore its dedication to innovation and efficiency. Furthermore, with a robust pipeline of products in various stages of development, Alkem is well-equipped to navigate the dynamic regulatory landscape and competitive pressures in the industry. For investors, the blend of Alkem's established market position, commitment to quality, and proactive expansion strategy signals a compelling opportunity backed by solid fundamentals.
See Also
What is Alkem Laboratories Ltd's Total Receivables?
Total Receivables
30.6B
INR
Based on the financial report for Jun 30, 2024, Alkem Laboratories Ltd's Total Receivables amounts to 30.6B INR.
What is Alkem Laboratories Ltd's Total Receivables growth rate?
Total Receivables CAGR 5Y
19%
Over the last year, the Total Receivables growth was 43%. The average annual Total Receivables growth rates for Alkem Laboratories Ltd have been 23% over the past three years , 19% over the past five years .
You don't have any saved screeners yet
